WuXi Biologics (2269.HK), a China-based global company with open-access biologics technology platforms, announced on Monday that it has completed a remote GMP inspection by South Korea's Ministry of Food and Drug Safety for its drug substance facility in Wuxi city.

The company has completed 23 regulatory inspections carried out by multiple regulatory agencies including U.S. FDA, EMA and China NMPA. The comprehensive inspection was carried out by two inspectors and included the facility's quality processes and complete production system.

Dr Chris Chen, WuXi Biologics CEO, said, 'We are excited that we start off the year 2022 by completing the first regulatory inspection successfully. Our world-class quality system certified by major regulatory agencies is a strong testament of the highest global quality standards we adhere to. We are very motivated by the fact that the products manufactured by WuXi Biologics have helped treat patients in multiple countries and regions. WuXi Biologics will continue enabling global partners to deliver life-saving treatments quickly and effectively to the markets, with the aim of benefiting patients worldwide.'